Based on the provided medical report, the patient has Muscle-invasive bladder cancer (MIBC) and has undergone various treatments, including TURBT, cisplatin and gemcitabine chemotherapy, and pembrolizumab immunotherapy. The patient's current symptoms include increased frequency and urgency of urination, hematuria, pelvic pain, and nocturia. The patient also has chronic kidney disease (CKD) and has experienced treatment-related toxicities, including mild kidney damage and immune-related side effects.

Considering the patient's medical history and current symptoms, I have evaluated the provided clinical trials to find the most relevant ones. Here are the results:

1. **A Phase 2, Open-label, Multi-centre, Multi-national Interventional Trial to Evaluate the Efficacy and Safety of Erdafitinib (ERDA) Monotherapy and Erdafitinib (ERDA) and Cetrelimab (CET) Combination as Neoadjuvant Treatment in Cisplatin-ineligible Patients With Muscle-invasive Bladder Cancer (MIBC) Whose Tumours Express Fibroblast Growth Factor Receptor (FGFR) Gene Alterations**

This trial is relevant because the patient has MIBC, and the trial is specifically designed for cisplatin-ineligible patients. The patient's tumor may express FGFR gene alterations, which is a requirement for this trial. However, the patient's CKD and previous treatment-related toxicities may impact eligibility.

2. **An Open, Single Arm, Prospective, Phase II Clinical Study on the First-line Treatment of Recurrent or Metastatic Muscle Invasive Bladder Cancer With Cadonilimab(AK104) Plus Nab-Paclitaxel**

This trial is relevant because the patient has MIBC, and the trial is designed for patients with recurrent or metastatic disease. The trial's inclusion criteria include patients with measurable lesions, which the patient may have. However, the trial's exclusion criteria include patients with active autoimmune disease, which may be a concern given the patient's immune-related side effects from pembrolizumab.

The other trials are not as relevant due to various reasons:

* The first trial is designed for patients with non-muscle invasive bladder cancer (NMIBC), which is not the patient's diagnosis.
* The third trial is designed for patients with NMIBC, and the patient's diagnosis of MIBC makes them ineligible.
* The fourth trial is designed for patients with high-risk NMIBC, and the patient's diagnosis of MIBC makes them ineligible.

In conclusion, the two most relevant clinical trials for this patient are the Erdafitinib and Cetrelimab combination trial and the Cadonilimab and Nab-Paclitaxel trial. However, the patient's CKD and previous treatment-related toxicities may impact eligibility, and careful consideration of these factors will be necessary when evaluating potential clinical trial options.